Caseware UK (AP4) 2024.0.164 2024.0.164 2026-03-312026-03-312025-04-01falsetruefalse00falsefalse 15937592 2025-04-01 2026-03-31 15937592 2024-09-05 2025-03-31 15937592 2026-03-31 15937592 2025-03-31 15937592 2024-09-05 15937592 c:Director1 2025-04-01 2026-03-31 15937592 c:Director2 2025-04-01 2026-03-31 15937592 c:Director2 2026-03-31 15937592 c:Director3 2025-04-01 2026-03-31 15937592 c:Director4 2025-04-01 2026-03-31 15937592 c:Director4 2026-03-31 15937592 c:RegisteredOffice 2025-04-01 2026-03-31 15937592 d:FreeholdInvestmentProperty 2025-04-01 2026-03-31 15937592 d:FreeholdInvestmentProperty 2026-03-31 15937592 d:FreeholdInvestmentProperty 2025-03-31 15937592 d:FreeholdInvestmentProperty 2 2025-04-01 2026-03-31 15937592 d:FreeholdInvestmentProperty 4 2025-04-01 2026-03-31 15937592 d:CurrentFinancialInstruments 2026-03-31 15937592 d:CurrentFinancialInstruments 2025-03-31 15937592 d:Non-currentFinancialInstruments 2026-03-31 15937592 d:Non-currentFinancialInstruments 2025-03-31 15937592 d:Non-currentFinancialInstruments 1 2026-03-31 15937592 d:Non-currentFinancialInstruments 1 2025-03-31 15937592 d:CurrentFinancialInstruments d:WithinOneYear 2026-03-31 15937592 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 15937592 d:Non-currentFinancialInstruments d:AfterOneYear 2026-03-31 15937592 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 15937592 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2026-03-31 15937592 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-03-31 15937592 d:UKTax 2025-04-01 2026-03-31 15937592 d:UKTax 2024-09-05 2025-03-31 15937592 d:ShareCapital 2026-03-31 15937592 d:ShareCapital 2024-09-05 2025-03-31 15937592 d:ShareCapital 2025-03-31 15937592 d:ShareCapital 2024-09-05 15937592 d:RetainedEarningsAccumulatedLosses 2025-04-01 2026-03-31 15937592 d:RetainedEarningsAccumulatedLosses 2026-03-31 15937592 d:RetainedEarningsAccumulatedLosses 2024-09-05 2025-03-31 15937592 d:RetainedEarningsAccumulatedLosses 2025-03-31 15937592 d:RetainedEarningsAccumulatedLosses 2024-09-05 15937592 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2026-03-31 15937592 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-03-31 15937592 c:FRS102 2025-04-01 2026-03-31 15937592 c:Audited 2025-04-01 2026-03-31 15937592 c:FullAccounts 2025-04-01 2026-03-31 15937592 c:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 15937592 2 2025-04-01 2026-03-31 15937592 f:PoundSterling 2025-04-01 2026-03-31 iso4217:GBP xbrli:pure

Registered number: 15937592









NSS HEALTHCARE 1 LTD









DIRECTORS' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

 
NSS HEALTHCARE 1 LTD
 
 
COMPANY INFORMATION


Directors
H W J Llewelyn 
H J Savory 
T G Thorp 




Registered number
15937592



Registered office
Eagle House First Floor
50 Marshall Street

London

W1F 9BQ




Independent auditor
S&W Audit
Chartered Accountants & Statutory Auditor

45 Gresham Street

London

EC2V 7BG





 
NSS HEALTHCARE 1 LTD
 

CONTENTS



Page
Directors' Report
1 - 2
Directors' Responsibilities Statement
3
Independent Auditor's Report
4 - 8
Statement of Comprehensive Income
9
Statement of Financial Position
10 - 11
Statement of Changes in Equity
12
Notes to the Financial Statements
13 - 26


 
NSS HEALTHCARE 1 LTD
 
 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2026

The directors present their report and the financial statements for the year ended 31 March 2026.

The prior period represents the period from incorporation on 5 September 2024 to 31 March 2025. For this reason, figures may not be fully comparable.

Principal activity

The principal objective of the Company is to hold investment property.

Going concern

The directors have prepared the financial statements on the going concern basis. Further details are provided in the notes to the financial statements.

Directors

The directors who served during the year were:

H W J Llewelyn 
N Sarkhel (resigned 31 August 2025)
H J Savory 
T G Thorp (appointed 29 September 2025)

Directors' indemnities

The Company has made qualifying third party indemnity provisions for the benefit of its directors which were made during the financial period and remain in force at the date of this report.
 
Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:
 
∙so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and

∙the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Auditor

The auditor, S&W Audit (a trading name of S&W Partners Audit Limited), will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

Page 1

 
NSS HEALTHCARE 1 LTD
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 





H W J Llewelyn
Director

Date: 12 August 2026

Page 2

 
NSS HEALTHCARE 1 LTD
 
 
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 MARCH 2026

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:

∙select suitable accounting policies for the Company's financial statements and then apply them consistently;

∙make judgements and accounting estimates that are reasonable and prudent; and


∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Page 3

 
img61d0.png 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NSS HEALTHCARE 1 LTD
 

Opinion

We have audited the financial statements of NSS Healthcare 1 Ltd (the 'Company') for the year ended  31 March 2026 which comprise the Statement of Comprehensive Income, the Statement of Financial Position, Statement of the Changes in Equity and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:
∙give a true and fair view of the state of the Company's affairs as at 31 March 2026 and of its profit for the year then ended; 
∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
∙have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Page 4

 
NSS HEALTHCARE 1 LTD
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NSS HEALTHCARE 1 LTD (CONTINUED)

Other information

The other information comprises the information included in the Directors' Report and Financial Statements, other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information contained within the Directors' Report and Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.  Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the Directors’ Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Directors’ Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors’ Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
∙the financial statements are not in agreement with the accounting records and returns; or
∙certain disclosures of directors’ remuneration specified by law are not made; or
∙we have not received all the information and explanations we require for our audit; or
∙the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the Directors' Report.
Page 5

 
NSS HEALTHCARE 1 LTD
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NSS HEALTHCARE 1 LTD (CONTINUED)

Responsibilities of directors

As explained more fully in the Directors’ Responsibilities Statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so. 

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists.  Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We obtained a general understanding of the company's legal and regulatory framework through enquiry of management in respect of their understanding of the relevant laws and regulations.

We understand that the Company complies with requirements of the framework through:
 
∙Maintaining clear policies; 
∙The directors' close involvement in the day-to-day running of the business, meaning that any litigation or claims would come to their attention directly and are considered at Board meetings; and 
∙Engaging external experts as required, including assistance with investment property valuations and tax compliance.
 
Page 6

 
NSS HEALTHCARE 1 LTD
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NSS HEALTHCARE 1 LTD (CONTINUED)

In the context of the audit, we considered those laws and regulations which determine the form and content of the financial statements, and which are central to the Company's ability to conduct its business and where failure to comply could result in material penalties. We have identified the following laws and regulations as being of significance in the context of the company;
 
∙Companies Act 2006 and FRS 102 in respect of the preparation and presentation of the financial statements; 
∙Health and Safety Legislation regarding building safety standards; and 
∙UK tax law.
 
We performed the following specific procedures to gain evidence about compliance with the significant laws and regulations identified above:
 
∙We made enquiries of management, including relating to legal correspondence, and reviewed board meeting minutes; and 
∙We obtained written management representations regarding disclosure of any non-compliance with laws and regulations.
 
The senior statutory auditor led a discussion with all members of the engagement team regarding susceptibility of the entity's financial statements to material misstatement, including how fraud might occur. The key areas identified in this discussion related to the potential manipulation of the financial statements through manual journal entries and inappropriate inputs to the valuation of investment property.

Audit procedures performed by the engagement team on the above areas included:
 
∙Testing a sample of manual journal entries, selected based on specific risk criteria which were identified taking into account the Company's business processes;
∙Performing planned audit procedures over the valuation process for investment property; and
∙Evaluating the appropriateness of the assumptions made within the valuation of investment property.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Page 7

 
NSS HEALTHCARE 1 LTD
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NSS HEALTHCARE 1 LTD (CONTINUED)

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose.  To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.



Thomas Norrie (Senior Statutory Auditor)
  
for and on behalf of
S&W Audit
 
Chartered Accountants
Statutory Auditor
  
45 Gresham Street
London
EC2V 7BG

12 August 2026
Page 8

 
NSS HEALTHCARE 1 LTD
 
 
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2026

Year ended
31 March
Period from 5 September 2024 to
31 March
2026
2025
Note
£
£

  

Turnover
  
2,829,689
1,356,152

Cost of sales
  
(663,709)
(253,006)

Gross profit
  
2,165,980
1,103,146

Administrative expenses
  
(558,274)
(16,272)

Fair value movements on investment property
  
1,772,673
938,894

Fair value movements on hedges
  
32,296
-

Operating profit
  
3,412,675
2,025,768

Interest receivable and similar income
  
27,243
384

Interest payable and similar expenses
  
(605,332)
-

Profit before tax
  
2,834,586
2,026,152

Tax on profit
 5 
84,431
(504,464)

Profit for the financial year/period
  
2,919,017
1,521,688

There was no other comprehensive income for the year ending 2026 (period from 5 September 2024 to 31 March 2025 - £Nil).

The notes on pages 13 to 26 form part of these financial statements.

Page 9

 
NSS HEALTHCARE 1 LTD
REGISTERED NUMBER:15937592

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2026

2026
2025
Note
£
£

Fixed assets
  

Investment property
 6 
33,130,000
31,065,000

Non-current assets
  

Debtors: amounts falling due after more than one year
 7 
96,210
-

Current assets
  

Debtors: amounts falling due within one year
 7 
1,209,623
1,005,138

Cash at bank and in hand
 8 
312,055
-

  
1,521,678
1,005,138

Creditors: amounts falling due within one year
 9 
(22,823,627)
(30,313,721)

Net current liabilities
  
 
 
(21,301,949)
 
 
(29,308,583)

Total assets less current liabilities
  
11,924,261
1,756,417

Creditors: amounts falling due after more than one year
 10 
(7,483,551)
-

Provisions for liabilities
  

Deferred tax
  
-
(234,724)

Net assets
  
4,440,710
1,521,693


Capital and reserves
  

Called up share capital 
  
5
5

Profit and loss account
  
4,440,705
1,521,688

Shareholders' funds
  
4,440,710
1,521,693


Page 10

 
NSS HEALTHCARE 1 LTD
REGISTERED NUMBER:15937592
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2026

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




H W J Llewelyn
Director

Date: 12 August 2026

The notes on pages 13 to 26 form part of these financial statements.

Page 11

 
NSS HEALTHCARE 1 LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026


Called up share capital
Profit and loss account
Total equity

£
£
£


At 5 September 2024
-
-
-


Comprehensive income for the period

Profit for the period
-
1,521,688
1,521,688


Contributions by and distributions to owners

Shares issued during the period
5
-
5



At 1 April 2025
5
1,521,688
1,521,693


Comprehensive income for the year

Profit for the year
-
2,919,017
2,919,017


At 31 March 2026
5
4,440,705
4,440,710


Page 12

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

1.


General information

NSS Healthcare 1 Limited is a private company, limited by shares, domiciled and incorporated in England and Wales (registered number: 15937592). The registered office address is Eagle House First Floor, 50 Marshall Street, London, England, W1F 9BQ.

The presentational currency of these financial statements is GBP (£).

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The Company has net assets of £4,440,710 and net current liabilities of £21,301,949.

The directors of the Company have performed an assessment, using forecasted cashflows using both normal and worst-case scenarios, for at least 12 months from the date of signing of these financial statements. The forecasts include the drawdown of a new third party bank loan (see note 12).

The directors have received written assurances from NSS V LP confirming they will not request repayment of any intercompany loans for a period of at least 12 months should the Company not be in a position to pay. The directors have considered NSS V LP's ability to provide these assurances and have satisfied themselves that they are able to do so.

The directors have concluded that the Company is well placed to manage its business risks successfully and have a reasonable expectation that the Company has adequate resources to continue its operational existence and meet its liabilities as they fall due for the foreseeable future.

The directors have also assessed the projected loan covenants and have a reasonable expectation that they are complying.

Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Page 13

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The Company is a subsidiary of NSS Healthcare Holdco Ltd which on 1 November 2025 became a UK REIT and as a result, profits are exempt from corporation tax on the profits and gains from its property rental business, provided it meets certain conditions set out in the UK REIT regulations (Note 6).


Page 14

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

  
2.6

Rental Income

Rental income, including any lease incentives received, are charged to the Statement of Comprehensive Income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

Rental income from operating leases is credited to the Statement of Comprehensive Income on a straight-line basis over the lease term.

Amounts paid and payable as an incentive to sign an operating lease are recognised as a reduction to income over the lease term on a straight-line basis, unless another systematic basis is representative of the time pattern over which the lessor's benefit from the leased asset is diminished.

 
2.7

Investment property

Investment property that is held for long-term rental yields or for capital appreciation or both, and that is not occupied by the Company is classified as investment property. Investment property also includes property that is being constructed or developed for future use and investment property.

The Company's holding of freehold and leasehold property interest is classified as investment property. Investment property is measured initially at cost, including related transaction costs, which also includes Stamp Duty Land Tax (SDLT). After initial recognition, investment property is carried at the fair value determined on the basis of independent valuations as at that date net of transaction costs, including SDLT. Fair value is based on open market prices, adjusted as necessary, for any difference in the nature, location or condition of the specific asset. The fair value of investment property reflects, among other things, rental income from current leases and assumptions about rental income from future leases in light of current market conditions.

Subsequent expenditure is charged to the asset's carrying amount only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be reliably measured. Unrealised gains and losses arising on revaluation of the investment property are included in the Statement of Comprehensive Income for the year.

Rent free (lease incentives) and capital incentives given to tenants are amortised over the term of the lease.

 
Page 15

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)


2.7
Investment property (continued)

Where the Company disposes of a property at fair value in an arm's length transaction, the carrying value immediately prior to the sale is adjusted to the transaction price, and the adjustment is recorded in the Statement of Comprehensive Income. When investment properties are transferred between entities under common control within the company structure, they are recorded at existing book cost. No profit or loss is recognised on such transfers. After transfer, the property continues to be accounted for in line with the company's policy on investment properties.

Investment properties are stated at fair value as at 31 March 2026 as determined by independent professional valuers.

The valuations are prepared in accordance with the professional standards, valuation technical and performance standards and valuation applications in accordance with the current version of the RICS Valuation - Global Standards and the RICS Valuation - Professional Standards UK (the 'Red Book'). The valuers hold relevant professional qualification with recent experience in the location and category of the investment property being valued.

In relation to fully developed investment property, the valuation is primarily derived using comparable recent market transactions on arm's length terms and using appropriate valuation techniques. The fair value of investment property is determined using the income capitalisation approach. Under this approach, forecast net cash flows, based upon current market derived estimated rental values together with estimated costs, are discounted at market derived capitalisation rates to assess fair value. All other factors remaining constant, an increase in capitalisation rates (significant input) would result in a fall in value and vice versa. An increase in estimated rental values will increase values and vice versa.

  
2.8

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Comprehensive Income as described below.

 
2.9

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Page 16

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.10

Financial instruments

The Company has elected to apply Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets and financial liabilities are recognised when the Company becomes party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

The Company's policies for its major classes of financial assets and financial liabilities are set out below.

Basic financial assets
Basic financial assets, including trade and other debtors, cash and bank balances and intercompany financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not market rate,

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

Basic financial liabilities
Basic financial liabilities, including trade and other creditors, bank loans and loans from fellow group companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest method.

 
Page 17

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)


2.10
Financial instruments (continued)

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income. 

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the Company would receive for the asset if it were to be sold at the reporting date. 

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in the Statement of Comprehensive Income.

Derivative financial instruments
The Company uses derivative financial instruments to reduce exposure to interest rate movements. The Company does not hold or issue derivative financial instruments for speculative purposes.

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and subsequently remeasured to their fair value at each reporting date. The resulting gain or loss is recognised in the Statement of Comprehensive Income immediately.
Page 18

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

3.


Judgements in applying accounting policies and key sources of estimation uncertainty

In the application of the Company's accounting policies, the directors are required to make judgements that have a significant impact on the amounts recognised. The following are the critical judgements that the directors have made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

Fair value of investment property
 
The fair value of investment property is determined by using valuation techniques. There are inter- relationships between unobservable inputs. Expected vacancy rates may impact the yield with higher vacancy rates resulting in higher yields. An increase in the future rental income may be linked with higher costs. If the remaining lease term increases, the yield may decrease. For further details, see note 7.

Derivatives

The Company obtains valuations performed by external valuers in order to determine the fair value of the derivatives. The fair value of the  Company's interest rate swap is determined by external valuers using valuation techniques that require judgement in selecting appropriate market assumptions, including discount rates and forward interest rate curves. These estimates are based on observable market data where available, but where such data is not available, management applies judgement to determine the most appropriate inputs. Changes in these assumptions could have a material impact on the fair value recognised in the financial statements.


4.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2025 - £Nil).

Page 19

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

5.


Taxation


Year ended
31 March
Period from 5 September 2024 to
31 March
2026
2025
£
£

Corporation tax


Current tax on profits for the year
150,293
269,740

Deferred tax


Origination and reversal of timing differences
(234,724)
234,724


Tax on profit
(84,431)
504,464


The Company is a subsidiary of NSS Healthcare Holdco Ltd which became a REIT on 1 November 2025 and as a result it, and all of its wholly owned subsidiaries do not pay UK corporation tax on the profits and gains from its qualifying property rental business in the UK provided it meets certain conditions.

Non-qualifying profits and gains from the Company continue to be subject to corporation tax as normal. In order to achieve and retain group REIT status, several conditions have to be met on entry to the regime and on an ongoing basis, including as follows:

∙At the start of each accounting period, the assets of the property rental business (plus cash and certain readily realisable investments) must be at least 75% of the total value of the Group's assets.
∙At least 75% of the Group's total profits must arise from the tax exempt property rental business; and
∙At least 90% of the tax-exempt profit of the property rental business (excluding gains) of the accounting period should be distributed.

Page 20

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
 
5.Taxation (continued)


Factors affecting tax charge for the year/period

The tax assessed for the year/period is lower than (2025 -lower than) the standard rate of corporation tax in the UK of 25% (2025 -25%). The differences are explained below:

Year ended
31 March
Period from 5 September 2024 to
31 March
2026
2025
£
£


Profit on ordinary activities before tax
2,834,586
2,026,152


Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2025 - 25%)
708,647
506,538

Effects of:


Expense not deductible for tax purposes
57,036
-

Income not taxable in determining taxable profit
(482,688)
(234,724)

Chargeable gains/losses
(234,723)
234,724

Remeasurement of deferred tax for changes in tax
(117,103)
-

Exempt profits adjustment
(130,073)
-

Movement in deferred tax not recognised
117,101
-

Group relief (claimed)
(2,628)
(2,074)

Total tax charge for the year/period
(84,431)
504,464


Factors that may affect future tax charges

There were no factors that may affect future tax charges.

Page 21

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

6.


Investment property


Freehold investment property

£



Valuation


At 1 April 2025
31,065,000


Additions at cost
42,327


Surplus on revaluation
1,772,673


Lease incentives
250,000



At 31 March 2026
33,130,000

The 2026 valuations were made by Avison Young, on an open market value basis.



If the Investment properties had been accounted for under the historic cost accounting rules, the properties would have been measured as follows:

2026
2025
£
£


Historic cost
30,418,433
30,376,106

Page 22

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

7.


Debtors

2026
2025
£
£

Due after more than one year

Derivative financial instruments
96,210
-


2026
2025
£
£

Due within one year

Trade debtors
24,582
441,723

Other debtors
1,153,384
494,825

Prepayments and accrued income
31,657
68,590

1,209,623
1,005,138


The other debtors balance includes amounts of £1,102,059 (2025 - £483,825) held by the property manager from rental and service charge income which will be transferred to the company at a later date. The balance is not available to cover costs.


8.


Cash and cash equivalents

2026
2025
£
£

Cash at bank and in hand
312,055
-


Page 23

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

9.


Creditors: Amounts falling due within one year

2026
2025
£
£

Trade creditors
321,231
-

Amounts owed to group undertakings
20,985,882
29,031,493

Corporation tax
150,293
269,740

Other taxation and social security
196,802
123,323

Other creditors
740,914
508,842

Accruals and deferred income
428,505
380,323

22,823,627
30,313,721


Included in amounts owed to Parent undertakings is £20,985,882 (2025 - £29,031,493) which relates to an amount payable to NSS Healthcare Holdco Ltd. These amounts are unsecured, interest-free, and repayable on demand. 


10.


Creditors: Amounts falling due after more than one year

2026
2025
£
£

Bank loans
7,483,551
-


Page 24

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

11.


Loans


Analysis of the maturity of loans is given below:


2026
2025
£
£


Amounts falling due 1-2 years

Bank loans
7,483,551
-


On 2 April 2025, NSS Healthcare 1 Ltd and NSS Healthcare 2 Ltd jointly borrowed a loan with HSBC UK Bank PLC in the amount of £24,750,000 of which £12,375,000 has been drawn. Both joint borrowers are unconditionally jointly and severally liable for the total loan amount. The rate of interest on the loan is charged for any day during an interest period as the aggregate of the margin (1.75% p.a.) and the compounded reference rate for that day. The loan matures on 1 April 2028.

On 2 April 2025, the Company also purchased a SWAP with a notional amount of £12,375,000 at a fixed rate of 3.75% expiring on 13 October 2029. The SWAP is jointly held between NSS Healthcare 1 Ltd and NSS Healthcare 2 Ltd.


12.


Financial instruments

2026
2025
£
£

Financial assets


Financial assets measured at fair value through profit or loss
96,210
-




Financial assets measured at fair value through profit or loss comprise derivative financial instruments.


13.


Related party transactions

The Company has taken advantage of the exemption available in FRS 102 section 33.1A from disclosing transactions with the ultimate parent company or any wholly owned subsidiary undertakings of the group.

Page 25

 
NSS HEALTHCARE 1 LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

14.


Controlling party

The Company's immediate parent company is NSS Healthcare Holdco Ltd, a company registered in England and Wales.

The Company's ultimate parent undertaking is Newcore Strategic Situations V LP, a Limited Partnership registered in England and Wales.

The smallest group of undertakings for which group accounts for the period ending 31 March 2026 have been drawn up, is that headed by NSS Healthcare Holdco Ltd. The registered office address of NSS Healthcare Holdco Ltd is Eagle House First Floor, 50 Marshall Street, London, W1F 9BQ. Copies of the Group accounts are available from Companies House.

The largest group of undertakings for which group accounts for the period ending 31 March 2026 have been drawn up, is that headed by Newcore Strategic Situations V LP. The registered office address of Newcore Strategic Situations V LP is Eagle House First Floor, 50 Marshall Street, London, W1F 9BQ. Copies of the Group accounts are not publicly available.

The directors do not consider there to be an ultimate controlling party.

Page 26